TITF1 signature biomarkers for early lung cancer detection

Lung cancer is more often curable when detected early in its course. Therefore, new approaches that enable the earlier detection of lung cancer are needed. Blood-based biomarkers represent one such approach. Here, we propose to combine a biology-based hypothesis with a genomic-scale exploration, to discover novel blood-based biomarkers. Our studies are based on TITF1, a transcription factor that functions in normal lung development, and is abnormally reactivated in lung cancers. We propose to identify the genes that are transcriptionally activated by TITF1 in lung cancers. Of these, we will further identify the subset encoding secreted proteins, and determine if they are also detectable in the blood of patients with lung cancer. Preliminary studies from our lab, and from mouse lung cancer models, support the rationale. Our studies will lead to the nomination and initial evaluation of novel blood-based biomarkers for the early detection of lung cancer, and may ultimately assist in early detection improving patient outcomes.